Latest News and Press Releases

SYDNEY, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced...

SYDNEY, Australia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...

SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...

Highlights: Recce’s new Anti-Infective Research Unit located within Murdoch Children's world-leading research facilities – internationally recognized for medical research breakthroughsFit-for-purpose...

Highlights: Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical ResearchStudy will...

Highlights: RECCE® 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal modelsNew patents lodged supporting anti-infective...

Highlights: Phase 1 safety and tolerability study of RECCE® 327 (R327) advancing to a Phase 1b/2a multi-dose and sepsis efficacy studyInitiating two new Phase 2 trials of R327 for the treatment of...

SYDNEY, Australia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company) is pleased to announce the appointment of Alistair McKeough to its Board of...

Highlights: 10 subjects in cohort seven were intravenously dosed with RECCE® 327 at 6,000mg Independent Safety Committee reviewing cohort seven data and anticipate a recommendation to proceed to...

– Dr. Sutton to help advance Recce’s portfolio of infectious disease programs focused on significant unmet medical needs – SYDNEY Australia, July 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals...